HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Pharming (NASDAQ:PHAR) and maintained a $37 price target.
August 04, 2023 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pharming's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $37 price target.
Analyst ratings often influence the short-term movement of a stock. A reiterated 'Buy' rating indicates confidence in the company's performance, which can lead to increased investor interest and potentially a rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100